Kalaris Therapeutics Inc (KLRS) vs RenovoRx, Inc. (RNXT)
A side-by-side comparison of Kalaris Therapeutics Inc and RenovoRx, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KLRS
Kalaris Therapeutics Inc
$2.66HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RNXT
RenovoRx, Inc.
$1.39HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — KLRS vs RNXT
growth of $100 · dividends reinvested · last 5yKLRS -100.0% (-80.5%/yr)RNXT -79.8% (-27.3%/yr)RNXT compounded faster over this window
Log scale — wide-divergence pair
KLRS RNXT
KLRS vs RNXT: by the numbers
- •RNXT is the larger company ($63M vs $58M market cap).
- •Both run net losses; KLRS's is the smaller (0.00% vs -621.71% net margin).
Metrics side by side
Valuation
| Metric | KLRS | RNXT |
|---|---|---|
| P/S ratio | N/A | 31.69 |
| P/B ratio | 1.01 | 6.97 |
Profitability
| Metric | KLRS | RNXT |
|---|---|---|
| Gross margin | 0.00% | 70.88% |
| Operating margin | 0.00% | -1113.98% |
| Net margin | 0.00% | -621.71% |
| ROE | -76.75% | -136.82% |
| ROIC | -52.40% | -139.74% |
Growth (annualized)
| Metric | KLRS | RNXT |
|---|---|---|
| Total return CAGR (5Y) | -81.13% | -23.80% |
Frequently asked
- How have KLRS and RNXT total returns compared?
- Over the past 5 years, KLRS delivered -81.13% and RNXT delivered -23.80% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.